Who are Zepatier Oral Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OBV/PTV/r and DSV, Zepatier plus Sofosbuvir, DCV/ASV/BMS-791325.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zepatier-oral-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Zepatier Oral Product — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zepatier Oral Product (Zepatier Oral Product) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NS5A inhibitor, NS3/4A protease inhibitor. Area: Infectious Diseases.

phase 3 NS5A inhibitor, NS3/4A protease inhibitor NS5A, NS3/4A protease Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Zepatier Oral Product (Zepatier Oral Product) — Kaohsiung Medical University Chung-Ho Memorial Hospital. Zepatier is a combination of elbasvir and grazoprevir, which are inhibitors of the hepatitis C virus NS5A and NS3/4A proteases, respectively.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Zepatier Oral Product TARGET	Zepatier Oral Product	Kaohsiung Medical University Chung-Ho Memorial Hospital	phase 3	NS5A inhibitor, NS3/4A protease inhibitor	NS5A, NS3/4A protease
OBV/PTV/r and DSV	OBV/PTV/r and DSV	Hannover Medical School	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B polymerase
Zepatier plus Sofosbuvir	Zepatier plus Sofosbuvir	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B RNA polymerase
DCV/ASV/BMS-791325	DCV/ASV/BMS-791325	Bristol-Myers Squibb	phase 3	Direct-acting antiviral combination (NS5A inhibitor + NS3 protease inhibitor + NS5B polymerase inhibitor)	HCV NS5A, NS3/4A protease, NS5B polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NS5A inhibitor, NS3/4A protease inhibitor class)

Kaohsiung Medical University Chung-Ho Memorial Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zepatier Oral Product — Competitive Intelligence Brief. https://druglandscape.com/ci/zepatier-oral-product. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab